Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report)'s share price was down 3.1% during trading on Thursday . The company traded as low as $3.95 and last traded at $4.02. Approximately 90,613 shares were traded during trading, a decline of 49% from the average daily volume of 176,830 shares. The stock had previously closed at $4.15.
Design Therapeutics Stock Up 1.8%
The firm has a 50-day moving average of $3.81 and a two-hundred day moving average of $4.18. The company has a market capitalization of $229.92 million, a PE ratio of -4.09 and a beta of 1.56.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). Equities analysts predict that Design Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.
Hedge Funds Weigh In On Design Therapeutics
Several institutional investors have recently bought and sold shares of the company. Velan Capital Investment Management LP purchased a new stake in Design Therapeutics during the first quarter worth approximately $54,000. Jane Street Group LLC acquired a new position in shares of Design Therapeutics in the first quarter valued at approximately $70,000. Invesco Ltd. acquired a new position in shares of Design Therapeutics in the fourth quarter valued at approximately $71,000. ProShare Advisors LLC acquired a new position in Design Therapeutics during the fourth quarter worth $71,000. Finally, Strs Ohio acquired a new position in Design Therapeutics during the first quarter worth $87,000. 56.64% of the stock is owned by institutional investors and hedge funds.
Design Therapeutics Company Profile
(
Get Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Read More
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
